Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Spatial Biomarker Deep Learning Model Predicts Response to PI3K Inhibition in Head and Neck Cancer.
Journal: Cancers
Published: April 10, 2026
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study.
Journal: Targeted oncology
Published: December 30, 2024
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.
Journal: Targeted oncology
Published: August 14, 2024
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I-III studies.
Journal: British journal of clinical pharmacology
Published: March 08, 2024
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302.
Journal: CPT: pharmacometrics & systems pharmacology
Published: June 27, 2023
Can a propensity score matching method be applied to assessing efficacy from single-arm proof-of-concept trials in oncology?
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 23, 2023
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.
Journal: British journal of cancer
Published: January 20, 2023
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Journal: Molecular cancer therapeutics
Published: February 11, 2021
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 20, 2020
Oncology phase II proof-of-concept studies with multiple targets: Randomized controlled trial or single arm?
Journal: Pharmaceutical statistics
Published: October 29, 2018
Characterization of murine CEACAM1 in vivo reveals low expression on CD8+ T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1.
Journal: Oncotarget
Published: June 21, 2018
Last Updated: 09/26/2026